Andreeva, VA, Galan, P, Torres, M, Julia, C, Hercberg, S, Kesse-Guyot, E.
Supplementation with B vitamins or n-3 fatty acids and depressive symptoms in cardiovascular disease survivors: ancillary findings from the SUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acids (SU.FOL.OM3) randomised trial. Am J Clin Nutr
2012; 96: 208–14.
Bot, M, Pouwer, F, Assies, J, Jansen, EH, Diamant, M, Snoek, FJ, et al.
Eicosapentaenoic acid as an add-on to antidepressant medication for comorbid major depression in patients with diabetes mellitus: a randomized, double-blind placebo-controlled study. J Affect Disord
2010; 126: 282–6.
Carney, RM, Freedland, KE, Rubin, EH, Rich, MW, Steinmeyer, BC, Harris, WS.
Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA
2009; 302: 1651–7.
da Silva, TM, Munhoz, RP, Alvarez, C, Naliwaiko, K, Kiss, A, Andreatini, R, et al.
Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord
2008; 111: 351–9.
Doornbos, B, van Goor, SA, Dijck-Brouwer, DA, Schaafsma, A, Korf, J, Muskiet, FA.
Supplementation of a low dose of DHA or DHA+AA does not prevent peripartum depressive symptoms in a small population based sample. Prog Neuropsychopharmacol Biol Psychiatry
2009; 33: 49–52.
Frangou, S, Lewis, M, McCrone, P.
Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry
2006; 188: 46–50.
Freeman, MP, Davis, M, Sinha, P, Wisner, KL, Hibbeln, JR, Gelenberg, AJ.
Omega-3 fatty acids and supportive psychotherapy for perinatal depression: a randomized placebo-controlled study. J Affect Disord
2008; 110: 142–8.
Freund-Levi, Y, Basun, H, Cederholm, T, Faxen-Irving, G, Garlind, A, Grut, M, et al.
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms. Int J Geriatr Psychiatry
2008; 23: 161–9.
Gertsik, L, Poland, RE, Bresee, C, Rapaport, MH.
Omega-3 fatty acid augmentation of citalopram treatment for patients with major depressive disorder. J Clin Psychopharmacol
2012; 32: 61–4.
Giltay, EJ, Geleijnse, JM, Kromhout, D.
Effects of n-3 fatty acids on depressive symptoms and dispositional optimism after myocardial infarction. Am J Clin Nutr
2011; 94: 1442–50.
Grenyer, BF, Crowe, T, Meyer, B, Owen, AJ, Grigonis-Deane, EM, Caputi, P, et al.
Fish oil supplementation in the treatment of major depression: a randomised double-blind placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry
2007; 31: 1393–6.
Hallahan, B, Hibbeln, JR, Davis, JM, Garland, MR.
Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial. Br J Psychiatry
2007; 190: 118–22.
Jazayeri, S, Tehrani-Doost, M, Keshavarz, SA, Hosseini, M, Djazayery, A, Amini, H, et al.
Comparison of therapeutic effects of omega-3 fatty acid eicosapentaenoic acid and fluoxetine, separately and in combination, in major depressive disorder. Aust NZ J Psychiatry
2008; 42: 192–8.
Kiecolt-Glaser, JK, Belury, MA, Andridge, R, Malarkey, WB, Hwang, BS, Glaser, R.
Omega-3 supplementation lowers inflammation in healthy middle-aged and older adults: a randomized controlled trial. Brain Behav Immun
2012; 26: 988–95.
Lesperance, F, Frasure-Smith, N, St-Andre, E, Turecki, G, Lesperance, P, Wisniewski, SR.
The efficacy of omega-3 supplementation for major depression: a randomized controlled trial. J Clin Psychiatry
2011; 72: 1054–62.
Llorente, AM, Jensen, CL, Voigt, RG, Fraley, JK, Berretta, MC, Heird, WC.
Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol
2003; 188: 1348–53.
Lucas, M, Asselin, G, Merette, C, Poulin, MJ, Dodin, S.
Ethyl-eicosapentaenoic acid for the treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr
2009; 89: 641–51.
Makrides, M, Gibson, RA, McPhee, AJ, Yelland, L, Quinlivan, J, Ryan, P, et al.
Effect of DHA supplementation during pregnancy on maternal depression and neurodevelopment of young children: a randomized controlled trial. JAMA
2010; 304: 1675–83.
Marangell, LB, Martinez, JM, Zboyan, HA, Kertz, B, Kim, HF, Puryear, LJ.
A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry
2003; 160: 996–8.
Mattes, E, McCarthy, S, Gong, G, van Eekelen, JA, Dunstan, J, Foster, J, et al.
Maternal mood scores in mid-pregnancy are related to aspects of neonatal immune function. Brain Behav Immun
2009; 23: 380–8.
Mischoulon, D, Papakostas, GI, Dording, CM, Farabaugh, AH, Sonawalla, SB, Agoston, AM, et al.
A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorder. J Clin Psychiatry
2009; 70: 1636–44.
Mozaffari-Khosravi, H, Yassini-Ardakani, M, Karamati, M, Shariati-Bafghi, SE.
Eicosapentaenoic acid versus docosahexaenoic acid in mild-to-moderate depression: a randomized, double-blind, placebo-controlled trial. Eur Neuropsychopharmacol
2013; 23: 636–44.
Nemets, B, Stahl, Z, Belmaker, RH.
Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry
2002; 159: 477–9.
Nemets, H, Nemets, B, Apter, A, Bracha, Z, Belmaker, RH.
Omega-3 treatment of childhood depression: a controlled, double-blind pilot study. Am J Psychiatry
2006; 163: 1098–100.
Peet, M, Horrobin, DF.
A dose-ranging study of the effects of ethyl-eicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry
2002; 59: 913–9.
Poppitt, SD, Howe, CA, Lithander, FE, Silvers, KM, Lin, RB, Croft, J, et al.
Effects of moderate-dose omega-3 fish oil on cardiovascular risk factors and mood after ischemic stroke: a randomized, controlled trial. Stroke
2009; 40: 3485–92.
Rees, AM, Austin, MP, Parker, GB.
Omega-3 fatty acids as a treatment for perinatal depression: randomized double-blind placebo-controlled trial. Aust NZ J Psychiatry
2008; 42: 199–205.
Rondanelli, M, Giacosa, A, Opizzi, A, Pelucchi, C, La Vecchia, C, Montorfano, G, et al.
Effect of omega-3 fatty acids supplementation on depressive symptoms and on health-related quality of life in the treatment of elderly women with depression: a double-blind, placebo-controlled, randomized clinical trial. J Am Coll Nutr
2010; 29: 55–64.
Silvers, KM, Woolley, CC, Hamilton, FC, Watts, PM, Watson, RA.
Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids
2005; 72: 211–8.
Sinn, N, Milte, CM, Street, SJ, Buckley, JD, Coates, AM, Petkov, J, et al.
Effects of n-3 fatty acids, EPA v. DHA, on depressive symptoms, quality of life, memory and executive function in older adults with mild cognitive impairment: a 6-month randomised controlled trial. Br J Nutr
2012; 107: 1682–93.
Stoll, AL, Severus, WE, Freeman, MP, Rueter, S, Zboyan, HA, Diamond, E, et al.
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry
1999; 56: 407–12.
Su, KP, Huang, SY, Chiu, CC, Shen, WW.
Omega-3 fatty acids in major depressive disorder. A preliminary double-blind, placebo-controlled trial. Eur Neuropsychopharmacol
2003; 13: 267–71.
Su, KP, Huang, SY, Chiu, TH, Huang, KC, Huang, CL, Chang, HC, et al.
Omega-3 fatty acids for major depressive disorder during pregnancy: results from a randomized, double-blind, placebo-controlled trial. Clin Psychiatry
2008; 69: 644–51.
Tajalizadekhoob, Y, Sharifi, F, Fakhrzadeh, H, Mirarefin, M, Ghaderpanahi, M, Badamchizade, Z, et al.
The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study. Eur Arch Psychiatry Clin Neurosci
2011; 261: 539–49.
van de Rest, O, Geleijnse, JM, Kok, FJ, van Staveren, WA, Hoefnagels, WH, Beekman, AT, et al.
Effect of fish-oil supplementation on mental well-being in older subjects: a randomized, double-blind, placebo-controlled trial. Am J Clin Nutr
2008; 88: 706–13.
Ross, BM, Seguin, J, Sieswerda, LE.
Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis
2007; 6: 21.
Martins, JG, Bentsen, H, Puri, BK.
Eicosapentaenoic acid appears to be the key omega-3 fatty acid component associated with efficacy in major depressive disorder: a critique of Bloch and Hannestad and updated meta-analysis. Mol Psychiatry
2012; 17: 1144–9; discussion 63–7.
Sublette, ME, Ellis, SP, Geant, AL, Mann, JJ.
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression. J Clin Psychiatry
2011; 72: 1577–84.
Appleton, KM, Hayward, RC, Gunnell, D, Peters, TJ, Rogers, PJ, Kessler, D, et al.
Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr
2006; 84: 1308–16.
Appleton, KM, Rogers, PJ, Ness, AR.
Updated systematic review and meta-analysis of the effects of n-3 long-chain polyunsaturated fatty acids on depressed mood. Am J Clin Nutr
2010; 91: 757–70.
Bloch, MH, Hannestad, J.
Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry
2012; 17: 1272–82.
Bloch, MHH J.
Response to critiques on ‘Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis’. Mol Psychiatry
2012; 17: 1163–7.
Caughey, GE, Mantzioris, E, Gibson, RA, Cleland, LG, James, MJ.
The effect on human tumor necrosis factor alpha and interleukin 1 beta production of diets enriched in n-3 fatty acids from vegetable oil or fish oil. Am J Clin Nutr
1996; 63: 116–22.
Kirsch, I, Deacon, BJ, Huedo-Medina, TB, Scoboria, A, Moore, TJ, Johnson, BT.
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med
2008; 5: e45.
Fournier, JC, DeRubeis, RJ, Hollon, SD, Dimidjian, S, Amsterdam, JD, Shelton, RC, et al.
Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA
2010; 303: 47–53.
American College of Neuropsychopharmacology. ACNP 49th Annual Meeting Final Program (available at www.acnp.org/annualmeeting/programbooks.aspx). ACNP, 2010.
Rogers, PJ, Appleton, KM, Kessler, D, Peters, TJ, Gunnell, D, Hayward, RC, et al.
No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr
2008; 99: 421–31.
Lucas, M, Asselin, G, Merette, C, Poulin, MJ, Dodin, S.
Effects of ethyl-eicosapentaenoic acid omega-3 fatty acid supplementation on hot flashes and quality of life among middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Menopause
2009; 16: 357–66.
Corbett, MSHJ, Woolacott, NF.
Assessing baseline imbalance in randomised controlled trials: implications for the Cochrane risk of bias tool. Res Syn Meth
2014; 5: 79–85.
Chiu, CC, Huang, SY, Chen, CC, Su, KP.
Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry
2005; 66: 1613–4.
Marangell, LB, Suppes, T, Ketter, TA, Dennehy, EB, Zboyan, H, Kertz, B, et al.
Omega-3 fatty acids in bipolar disorder: clinical and research considerations. Prostaglandins Leukot Essent Fatty Acids
2006; 75: 315–21.
Murphy, BL, Stoll, AL, Harris, PQ, Ravichandran, C, Babb, SM, Carlezon, WA Jr, et al.
Omega-3 fatty acid treatment, with or without cytidine, fails to show therapeutic properties in bipolar disorder: a double-blind, randomized add-on clinical trial. J Clin Psychopharmacol
2012; 32: 699–703.
Gracious, BL, Chirieac, MC, Costescu, S, Finucane, TL, Youngstrom, EA, Hibbeln, JR.
Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord
2010; 12: 142–54.
Krauss-Etschmann, S, Shadid, R, Campoy, C, Hoster, E, Demmelmair, H, Jimenez, M, et al.
Effects of fish-oil and folate supplementation of pregnant women on maternal and fetal plasma concentrations of docosahexaenoic acid and eicosapentaenoic acid: a European randomized multicenter trial. Am J Clin Nutr
2007; 85: 1392–400.
Keck, PE Jr, Mintz, J, McElroy, SL, Freeman, MP, Suppes, T, Frye, MA, et al.
Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry
2006; 60: 1020–2.
Novel metabolism of docosahexaenoic acid in neural cells. J Biol Chem
2007; 282: 18661–5.
McNamara, RK, Able, J, Liu, Y, Jandacek, R, Rider, T, Tso, P, et al.
Omega-3 fatty acid deficiency during perinatal development increases serotonin turnover in the prefrontal cortex and decreases midbrain tryptophan hydroxylase-2 expression in adult female rats: dissociation from estrogenic effects. J Psychiatr Res
2009; 43: 656–63.
Moriguchi, T, Loewke, J, Garrison, M, Catalan, JN, Salem, N Jr.
Reversal of docosahexaenoic acid deficiency in the rat brain, retina, liver, and serum. J Lipid Res
2001; 42: 419–27.
McNamara, RK, Hahn, CG, Jandacek, R, Rider, T, Tso, P, Stanford, KE, et al.
Selective deficits in the omega-3 fatty acid docosahexaenoic acid in the postmortem orbitofrontal cortex of patients with major depressive disorder. Biol Psychiatry
2007; 62: 17–24.
Umhau, JC, Zhou, W, Carson, RE, Rapoport, SI, Polozova, A, Demar, J, et al.
Imaging incorporation of circulating docosahexaenoic acid into the human brain using positron emission tomography. J Lipid Res
2009; 50: 1259–68.
A new category of psychotropic drugs: neuroactive lipids as exemplified by ethyl eicosapentaenoate (E-E). Prog Drug Res
2002; 59: 171–99.
Chen, CT, Domenichiello, AF, Trepanier, MO, Liu, Z, Masoodi, M, Bazinet, RP.
The low levels of eicosapentaenoic acid in rat brain phospholipids are maintained via multiple redundant mechanisms. J Lipid Res
2013; 54: 2410–22.
Gold, PW, Licinio, J, Pavlatou, MG.
Pathological parainflammation and endoplasmic reticulum stress in depression: potential translational targets through the CNS insulin, klotho and PPAR-gamma systems. Mol Psychiatry
2013; 18: 154–65.
Xu, HE, Lambert, MH, Montana, VG, Parks, DJ, Blanchard, SG, Brown, PJ, et al.
Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. Mol Cell
1999; 3: 397–403.
Lin, Q, Ruuska, SE, Shaw, NS, Dong, D, Noy, N.
Ligand selectivity of the peroxisome proliferator-activated receptor alpha. Biochemistry
1999; 38: 185–90.
Jump, DB, Tripathy, S, Depner, CM.
Fatty acid-regulated transcription factors in the liver. Annu Rev Nutr
2013; 33: 249–69.
Mochizuki, K, Suruga, K, Fukami, H, Kiso, Y, Takase, S, Goda, T.
Selectivity of fatty acid ligands for PPARalpha which correlates both with binding to cis-element and DNA binding-independent transactivity in Caco-2 cells. Life Sci
2006; 80: 140–5.
Popeijus, HE, van Otterdijk, SD, van der Krieken, SE, Konings, M, Serbonij, K, Plat, J, et al.
Fatty acid chain length and saturation influences PPARalpha transcriptional activation and repression in HepG2 cells. Mol Nutr Food Res
2014; 58: 2342–9.
Kemp, DE, Schinagle, M, Gao, K, Conroy, C, Ganocy, SJ, Ismail-Beigi, F, et al.
PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs
2014; 28: 571–81.
Stopponi, S, Somaini, L, Cippitelli, A, Cannella, N, Braconi, S, Kallupi, M, et al.
Activation of nuclear PPARgamma receptors by the antidiabetic agent pioglitazone suppresses alcohol drinking and relapse to alcohol seeking. Biol Psychiatry
2011; 69: 642–9.
Maes, M, Yirmyia, R, Noraberg, J, Brene, S, Hibbeln, J, Perini, G, et al.
The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis
2009; 24: 27–53.
Rapaport, MH, Nierenberg, AA, Schettler, PJ, Kinkead, B, Cardoos, A, Walker, R, et al.
Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry
2016; 21: 71–9.
Sarkar, S, Schaefer, M.
Antidepressant pretreatment for the prevention of interferon alfa-associated depression: a systematic review and meta-analysis. Psychosomatics
2014; 55: 221–34.
Su, KP, Lai, HC, Yang, HT, Su, WP, Peng, CY, Chang, JP, et al.
Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry
2014; 76: 559–66.
Song, C, Zhang, XY, Manku, M.
Increased phospholipase A2 activity and inflammatory response but decreased nerve growth factor expression in the olfactory bulbectomized rat model of depression: effects of chronic ethyl-eicosapentaenoate treatment. J Neurosci
2009; 29: 14–22.
Wu, A, Ying, Z, Gomez-Pinilla, F.
Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J Neurotrauma
2004; 21: 1457–67.
Rao, MS, Hattiangady, B, Shetty, AK.
Fetal hippocampal CA3 cell grafts enriched with FGF-2 and BDNF exhibit robust long-term survival and integration and suppress aberrant mossy fiber sprouting in the injured middle-aged hippocampus. Neurobiol Dis
2006; 21: 276–90.
Taliaz, D, Stall, N, Dar, DE, Zangen, A.
Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis. Mol Psychiatry
2010; 15: 80–92.
Hoshaw, BA, Malberg, JE, Lucki, I.
Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res
2005; 1037: 204–8.
Grosso, G, Pajak, A, Marventano, S, Castellano, S, Galvano, F, Bucolo, C, et al.
Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PloS One
2014; 9: e96905.
Appleton, KM, Sallis, HM, Perry, R, Ness, AR, Churchill, R.
Omega-3 fatty acids for depression in adults. Cochrane Database Syst Rev
2015; 11: CD004692.